You are here

Article Text

Article menu
Download PDFPDF
Letter
Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease
  1. F Lanternier1,2,
  2. C Henegar1,3,
  3. L Mouthon1,2,
  4. P Blanche1,
  5. L Guillevin1,2,
  6. O Launay1,2,4
  1. 1
    Assistance Publique–Hôpitaux de Paris, Groupe Hospitalier Cochin-Saint Vincent de Paul, Pôle de Médecine, Paris, France
  2. 2
    Université Paris Descartes, Faculté de Médecine, Paris, France
  3. 3
    INSERM, U872, Les Cordeliers, Equipe 7 Nutriomique, Paris, France
  4. 4
    INSERM, CIC de Vaccinologie Cochin-Pasteur, Paris, France
  1. Dr O Launay, CIC de Vaccinologie Cochin-Pasteur, Pôle de Médecine, Groupe Hospitalier Cochin-Saint Vincent de Paul, 27 rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France; odile.launay{at}cch.aphp.fr

https://doi.org/10.1136/ard.2007.081703

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Although annual influenza vaccination is recommended for adults taking immunosuppressant drugs,1–3 the vaccination rate is suboptimal in these patients.4–6 We undertook a study to assess the flu-vaccination uptake of patients treated for systemic inflammatory diseases and to explore the factors that influence it. The study was approved by the Paris Ile de France III Ethics Committee (“Comité de Protection des Personnes Ile de France III”) Paris, France.

    We collected information about flu shots with a standardised form completed by the doctors of patients with systemic inflammatory diseases taking corticosteroids and/or immunosuppressant drugs, followed up in our internal medicine department during January 2006.

    One hundred and thirty-seven consecutive …

    View Full Text

    Footnotes

    • Competing interests: None declared.

    • Presented in part at the ACR 2006, Washington DC, poster number 212, and at IDSA 2006, Toronto, poster number 809.

    • Ethics approval: Approved by the Paris Ile de France III Ethics Committee.